Lisata Therapeutics (LSTA) Equity Average (2016 - 2025)
Lisata Therapeutics' Equity Average history spans 12 years, with the latest figure at $15.9 million for Q4 2025.
- For Q4 2025, Equity Average fell 49.45% year-over-year to $15.9 million; the TTM value through Dec 2025 reached $15.9 million, down 49.45%, while the annual FY2025 figure was $22.0 million, 43.12% down from the prior year.
- Equity Average reached $15.9 million in Q4 2025 per LSTA's latest filing, down from $18.9 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $59.2 million in Q2 2023 to a low of $15.9 million in Q4 2025.
- Average Equity Average over 3 years is $37.1 million, with a median of $38.0 million recorded in 2024.
- Peak YoY movement for Equity Average: rose 5.78% in 2024, then tumbled 49.45% in 2025.
- A 3-year view of Equity Average shows it stood at $50.3 million in 2023, then crashed by 37.62% to $31.4 million in 2024, then crashed by 49.45% to $15.9 million in 2025.
- Per Business Quant, the three most recent readings for LSTA's Equity Average are $15.9 million (Q4 2025), $18.9 million (Q3 2025), and $22.9 million (Q2 2025).